We evaluated serum leptin levels in 9 young chronic myeloid leukemia (CML) patients under imatinib therapy during a long-term follow-up. Body mass index (BMI) and fat mass percentage (%FM) were also measured. Leptin was above the normal range in 8 out of 9 patients. In one case the hormone was below the reference value. All subjects showed a normal BMI, but 3 had a small increase of FM%. One patient recovered the leptin normal value after imatinib suspension. A tendency to leptin normalization in patients switched to an intermittent therapy was also found. This study suggests that imatinib therapy may result in leptin alteration.
Leptin modification in chronic myeloid leukemia patients treated with imatinib: An emerging effect of targeted therapy / Mariani, S.; Basciani, S.; Giona, Fiorina; Lubrano, Carla; Ulisse, Salvatore; Gnessi, Lucio. - In: LEUKEMIA RESEARCH REPORTS. - ISSN 2213-0489. - STAMPA. - 2:2(2013), pp. 58-60. [10.1016/j.lrr.2013.07.001]
Leptin modification in chronic myeloid leukemia patients treated with imatinib: An emerging effect of targeted therapy
S. Mariani;GIONA, Fiorina;LUBRANO, Carla;ULISSE, SALVATORE;GNESSI, Lucio
2013
Abstract
We evaluated serum leptin levels in 9 young chronic myeloid leukemia (CML) patients under imatinib therapy during a long-term follow-up. Body mass index (BMI) and fat mass percentage (%FM) were also measured. Leptin was above the normal range in 8 out of 9 patients. In one case the hormone was below the reference value. All subjects showed a normal BMI, but 3 had a small increase of FM%. One patient recovered the leptin normal value after imatinib suspension. A tendency to leptin normalization in patients switched to an intermittent therapy was also found. This study suggests that imatinib therapy may result in leptin alteration.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
